Trials / Unknown
UnknownNCT05702268
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Moderate-to-severe Atopic Dermatitis
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-332 | Tablet, 40 mg |
| DRUG | ICP-332 Placebo | Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332. |
Timeline
- Start date
- 2023-03-18
- Primary completion
- 2023-07-30
- Completion
- 2023-12-30
- First posted
- 2023-01-27
- Last updated
- 2023-05-22
Locations
28 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05702268. Inclusion in this directory is not an endorsement.